


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER KLBS0005-100
INTERNATIONAL APPLICATION NO. PCT/GB2003/005035	INTERNATIONAL FILING DATE 18 November 2003	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/535280
TITLE OF INVENTION HISTONE DEACETYLASE INHIBITORS		
APPLICANT(S) FOR DO/EO/US Simon Joel, Charles Marson, Pascal Savy		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input checked="" type="checkbox"/> The US has been elected (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (UNEXECUTED)10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A preliminary amendment.14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A power of attorney and/or change of address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input checked="" type="checkbox"/> Other items or information: Communication including copy of Page 79 of PCT application as originally filed		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known—see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/GB2003/005035		ATTORNEY'S DOCKET NUMBER KLBS0005-100			
10/535280							
The following fees are submitted:							
21. <input checked="" type="checkbox"/> Basic national		\$300		CALCULATIONS	PTO USE ONLY		
		\$ 300.00					
22. <input checked="" type="checkbox"/> Examination Fee If international preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)						\$100	\$ 200.00
All other situations		\$200					
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2) has been paid on the international application to the USPTO as an International Searching Authority						\$100	\$ 400.00
International Search Report prepared and provided in the Office		\$400					
All other situations		\$500					
TOTAL OF 21, 22 and 23 =				\$ 900.00			
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		RATE			
92 - 100 =	0/50 =	0		x \$250	\$		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).							
CLAIMS	NUMBER FILED	NUMBER EXTRA		RATE			
Total claims	39 - 20 =	19		x \$50	\$ 950.00		
Independent claims	4 - 3 =	1		x \$200	\$ 200.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	\$ 0		
TOTAL OF ABOVE CALCULATIONS = \$1150.00							
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.							
SUBTOTAL = \$2050.00							
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							
+ \$							
TOTAL NATIONAL FEE = \$2050.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property							
+ \$							
TOTAL FEES ENCLOSED = \$2050.00							
Amount to be refunded: \$							
Amount to be charged: \$2050.00 \$							
a. <input type="checkbox"/>	A check in the amount of \$ _____ to cover the above fees is enclosed.						
b. <input checked="" type="checkbox"/>	Please charge my Deposit Account No. 50-1275 in the amount of \$ 2050.00 to cover the above fees.						
A duplicate copy of this sheet is enclosed.							
c. <input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1275. A duplicate copy of this sheet is enclosed.						
d. <input type="checkbox"/>	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO:							
 SIGNATURE Paul K. Legaard (Registration Number 38,534) NAME _____							

JC14 Rec'd PCT/PTO 17 MAY 2005

10/535280

The PTO did not receive the following
listed item(s)

NO POST CARD

10/535280
17 MAY 2005

DOCKET NO. KLBS0005-100

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Simon Joel, Charles Marson, Pascal Savy

Serial No.: Not Yet Assigned

Filed: Herewith

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Title: HISTONE DEACETYLASE INHIBITORS


Express Mail Label No. EV 513562771 US
Date of Deposit: May 17, 2005

Communication


Applicants include herewith a paper copy of Page 79 of the originally filed PCT application as identified above which includes a portion of claim 23 and claims 24 and 25 which were inadvertently omitted in the published application (WO 2004/046094 A1). This error was communicated to the International Bureau. The International Bureau has provided a Communication acknowledging the error and advising that a correction will be published in Section II of the PCT Gazette and that the corrected version of the corresponding PCT pamphlet will be published on the same date. The International Bureau further advises that a copy of the notification is being sent to the receiving office (RO/GB) and to the elected offices concerned.. A copy of the Communication received from the International Bureau is attached hereto. Pages 79-81 of the published application should be renumbered as Pages 80-82 once corrected.

Respectfully Submitted

COZEN O'CONNOR

By: 
Paul K. Legaard (Reg. No. 38,534)
Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
(215) 665-6914


Dated: May 17, 2005



17


optionally followed by hydrolysis, or oxidation then hydrolysis.

- 5 24. A process as claimed in any one of claims 21 to 23, in which the aldehyde compound corresponding to the product of the addition of a compound of general formula (II) to general formula (III), is reacted with a stabilised phosphorous ylid compound



10

or with a phosphonate compound of general formula:



15

25. A process as claimed in claim 24, in which the stabilised phosphorous ylid compound is (triphenylphosphanylidene)-acetic acid ethyl ester.

